KRAS/NRAS Mutations Associated with Distant Metastasis and BRAF/PIK3CA Mutations Associated with Poor Tumor Differentiation in Colorectal Cancer

References

• Sung H, Ferlay J, Siegel RL. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Cao W, Chen HD, Yu YW, Li N, Chen WQ. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020. Chin Med J. 2021;134(7):783–791. doi:10.1097/CM9.0000000000001474
   PubMed Web of Science ®Google Scholar
• Xie YH, Chen YX, Fang JY. Comprehensive review of targeted therapy for colorectal cancer. Signal Transduct Target Ther. 2020;5(1):22. doi:10.1038/s41392-020-0116-z
   PubMed Web of Science ®Google Scholar
• Martinelli E, Ciardiello D, Martini G, et al. Implementing anti-epidermal growth factor receptor (EGFR) therapy in metastatic colorectal cancer: challenges and future perspectives. Ann Oncol. 2020;31(1):30–40. doi:10.1016/j.annonc.2019.10.007
   PubMed Web of Science ®Google Scholar
• Chan DLH, Segelov E, Wong RS, et al. Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer. Cochrane Database Syst Rev. 2017;6(6):Cd007047. doi:10.1002/14651858.CD007047.pub2
   PubMedGoogle Scholar
• Sforza V, Martinelli E, Ciardiello F, et al. Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer. World J Gastroenterol. 2016;22(28):6345–6361. doi:10.3748/wjg.v22.i28.6345
   PubMed Web of Science ®Google Scholar
• Miyamoto Y, Suyama K, Baba H. Recent Advances in Targeting the EGFR Signaling Pathway for the Treatment of Metastatic Colorectal Cancer. Int J Mol Sci. 2017;18(4):752. doi:10.3390/ijms18040752
   PubMed Web of Science ®Google Scholar
• Khan K, Valeri N, Dearman C, et al. Targeting EGFR pathway in metastatic colorectal cancer- tumour heterogeneity and convergent evolution. Crit Rev Oncol Hematol. 2019;143:153–163. doi:10.1016/j.critrevonc.2019.09.001
   PubMed Web of Science ®Google Scholar
• Fitzmaurice C, Abate D, Abbasi N, et al. Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017: a Systematic Analysis for the Global Burden of Disease Study. JAMA Oncol. 2019;5(12):1749–1768. doi:10.1001/jamaoncol.2019.2996
   PubMed Web of Science ®Google Scholar
• Osseis M, Nehmeh WA, Rassy N, Derienne J. Surgery for T4 colorectal cancer in older patients: determinants of outcomes. J Pers Med. 2022;12(9):1534. doi:10.3390/jpm12091534
   PubMed Web of Science ®Google Scholar
• Michl M, Taverna F, Kumbrink J, et al. Biomarker alterations associated with distinct patterns of metastatic spread in colorectal cancer. Virchows Arch. 2021;478(4):695–705. doi:10.1007/s00428-020-02983-6
   PubMed Web of Science ®Google Scholar
• Lipsyc M, Yaeger R. Impact of somatic mutations on patterns of metastasis in colorectal cancer. J Gastrointest Oncol. 2015;6(6):645–649. doi:10.3978/j.issn.2078-6891.2015.045
   PubMed Web of Science ®Google Scholar
• Kleist B, Meurer T, Poetsch M. Mitochondrial DNA alteration in primary and metastatic colorectal cancer: different frequency and association with selected clinicopathological and molecular markers. Tumour Biol. 2017;39(3):1010428317692246. doi:10.1177/1010428317692246
   Google Scholar
• Zhang J, Zheng J, Yang Y, et al. Molecular spectrum of KRAS, NRAS, BRAF and PIK3CA mutations in Chinese colorectal cancer patients: analysis of 1110 cases. Sci Rep. 2015;5(1):18678. doi:10.1038/srep18678
   PubMedGoogle Scholar
• Shen Y, Wang J, Han X, et al. Effectors of epidermal growth factor receptor pathway: the genetic profiling ofKRAS, BRAF, PIK3CA, NRAS mutations in colorectal cancer characteristics and personalized medicine. PLoS One. 2013;8(12):e81628. doi:10.1371/journal.pone.0081628
   PubMed Web of Science ®Google Scholar
• Kawazoe A, Shitara K, Fukuoka S, et al. A retrospective observational study of clinicopathological features of KRAS, NRAS, BRAF and PIK3CA mutations in Japanese patients with metastatic colorectal cancer. BMC Cancer. 2015;15(1):258. doi:10.1186/s12885-015-1276-z
   PubMedGoogle Scholar
• Yaeger R, Cercek A, Chou JF, et al. BRAF mutation predicts for poor outcomes after metastasectomy in patients with metastatic colorectal cancer. Cancer. 2014;120(15):2316–2324. doi:10.1002/cncr.28729
   PubMed Web of Science ®Google Scholar
• Chang SC, Lin PC, Lin JK, et al. Mutation spectra of common cancer-associated genes in different phenotypes of colorectal carcinoma without distant metastasis. Ann Surg Oncol. 2016;23(3):849–855. doi:10.1245/s10434-015-4899-z
   PubMed Web of Science ®Google Scholar
• Achrol AS, Rennert RC, Anders C, et al. Brain metastases. Nat Rev Dis Primers. 2019;5(1):5. doi:10.1038/s41572-018-0055-y
   PubMed Web of Science ®Google Scholar
• Di Gregorio F, La Porta F, Petrone V, Battaglia S. Accuracy of EEG Biomarkers in the Detection of Clinical Outcome in Disorders of Consciousness after Severe Acquired Brain Injury: preliminary Results of a Pilot Study Using a Machine Learning Approach. Biomedicines. 2022;10(8):1897. doi:10.3390/biomedicines10081897
   PubMed Web of Science ®Google Scholar
• Ippolito G, Bertaccini R, Tarasi L. The role of alpha oscillations among the main neuropsychiatric disorders in the adult and developing human brain: evidence from the last 10 years of research. Biomedicines. 2022;10(12):3189. doi:10.3390/biomedicines10123189
   PubMed Web of Science ®Google Scholar
• Wang WZ, Wang CY, Cheng YT, et al. Tracing the origins of Hakka and Chaoshanese by mitochondrial DNA analysis. Am J Phys Anthropol. 2010;141(1):124–130. doi:10.1002/ajpa.21124
   PubMed Web of Science ®Google Scholar
• Bruni D, Angell HK. The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy. Nat Rev Cancer. 2020;20(11):662–680. doi:10.1038/s41568-020-0285-7
   PubMed Web of Science ®Google Scholar
• Dekker E, Tanis PJ, Vleugels JLA, Kasi PM, Wallace MB. Colorectal cancer. Lancet. 2019;394(10207):1467–1480. doi:10.1016/S0140-6736(19)32319-0
   PubMed Web of Science ®Google Scholar
• Boussios S, Ozturk MA. The developing story of predictive biomarkers in colorectal cancer. J Pers Med. 2019;9(1):12. doi:10.3390/jpm9010012
   PubMed Web of Science ®Google Scholar
• Markowitz SD, Bertagnolli MM. Molecular origins of cancer: molecular basis of colorectal cancer. N Engl J Med. 2009;361(25):2449–2460. doi:10.1056/NEJMra0804588
   PubMed Web of Science ®Google Scholar
• Wang MY, Qiu YH, Cai ML, et al. Role and molecular mechanism of stem cells in colorectal cancer initiation. J Drug Target. 2020;28(1):1–10. doi:10.1080/1061186X.2019.1632317
   PubMed Web of Science ®Google Scholar
• Garcia J, Hurwitz HI, Sandler AB, et al. Bevacizumab (Avastin®) in cancer treatment: a review of 15 years of clinical experience and future outlook. Cancer Treat Rev. 2020;86:102017. doi:10.1016/j.ctrv.2020.102017
   PubMed Web of Science ®Google Scholar
• Piawah S, Venook AP. Targeted therapy for colorectal cancer metastases: a review of current methods of molecularly targeted therapy and the use of tumor biomarkers in the treatment of metastatic colorectal cancer. Cancer. 2019;125(23):4139–4147. doi:10.1002/cncr.32163
   PubMed Web of Science ®Google Scholar
• Biller LH, Schrag D. Diagnosis and treatment of metastatic colorectal cancer: a review. JAMA. 2021;325(7):669–685. doi:10.1001/jama.2021.0106
   PubMed Web of Science ®Google Scholar
• Aleksakhina SN, Imyanitov EN. Cancer therapy guided by mutation tests: current status and perspectives. Int J Mol Sci. 2021;22(20):10931. doi:10.3390/ijms222010931
   PubMed Web of Science ®Google Scholar
• Timar J, Kashofer K. Molecular epidemiology and diagnostics of KRAS mutations in human cancer. Cancer Metastasis Rev. 2020;39(4):1029–1038. doi:10.1007/s10555-020-09915-5
   PubMed Web of Science ®Google Scholar
• Poulsen TS, de Oliveira D, Espersen MLM, Klarskov LL, Skovrider-Ruminski W, Hogdall E. Frequency and coexistence of KRAS, NRAS, BRAF and PIK3CA mutations and occurrence of MMR deficiency in Danish colorectal cancer patients. APMIS. 2021;129(2):61–69. doi:10.1111/apm.13091
   PubMed Web of Science ®Google Scholar
• Licar A, Cerkovnik P, Ocvirk J, Novakovic S. KRAS mutations in Slovene patients with colorectal cancer: frequency, distribution and correlation with the response to treatment. Int J Oncol. 2010;36(5):1137–1144. doi:10.3892/ijo_00000596
   PubMed Web of Science ®Google Scholar
• Alharbi A, Bin Dokhi H. Prevalence of colorectal cancer biomarkers and their impact on clinical outcomes in Riyadh, Saudi Arabia. PLoS One. 2021;16(5):e0249590. doi:10.1371/journal.pone.0249590
   PubMed Web of Science ®Google Scholar
• Uhlig J, Cecchini M, Sheth A, Stein S, Lacy J, Kim HS. Microsatellite Instability and KRAS Mutation in Stage IV Colorectal Cancer: prevalence, Geographic Discrepancies, and Outcomes From the National Cancer Database. J Natl Compr Canc Netw. 2021;19(3):307–318. doi:10.6004/jnccn.2020.7619
   PubMed Web of Science ®Google Scholar
• Yari A, Samoudi A. Mutation Status and Prognostic Value of KRAS and BRAF in Southeast Iranian Colorectal Cancer Patients: first Report from Southeast of Iran. J Gastrointest Cancer. 2021;52(2):557–568. doi:10.1007/s12029-020-00426-8
   PubMed Web of Science ®Google Scholar
• Bagci B, Sari M, Karadayi K, Turan M, Ozdemir O. BRAF oncogene mutations and tissue specific promoter hypermethylation of tumor suppressor SFRP2, DAPK1, MGMT, HIC1 and p16 genes in colorectal cancer patients. Cancer Biomark. 2016;17(2):133–143. doi:10.3233/CBM-160624
   PubMed Web of Science ®Google Scholar
• Ikoma T, Shimokawa M, Kotaka M, et al. Clinical and prognostic features of patients with detailed RAS/BRAF-mutant colorectal cancer in Japan. BMC Cancer. 2021;21(1):518. doi:10.1186/s12885-021-08271-z
   PubMed Web of Science ®Google Scholar
• Ta TV, Nguyen QN, Chu HH, Truong VL, Vuong LD. RAS/RAF mutations and their associations with epigenetic alterations for distinct pathways in Vietnamese colorectal cancer. Pathol Res Pract. 2020;216(4):152898. doi:10.1016/j.prp.2020.152898
   PubMed Web of Science ®Google Scholar
• Bagadi SB, Sanghvi M, Nair SB, Das BR. Combined mutational analysis of KRAS, NRAS and BRAF genes in Indian patients with colorectal carcinoma. Int J Biol Markers. 2012;27(1):27–33. doi:10.5301/JBM.2012.9108
   PubMed Web of Science ®Google Scholar
• Huang W, Li H, Shi X, et al. Characterization of genomic alterations in Chinese colorectal cancer patients. Jpn J Clin Oncol. 2021;51(1):120–129. doi:10.1093/jjco
   PubMed Web of Science ®Google Scholar
• Yuan Y, Liu Y, Wu Y, et al. Clinical characteristics and prognostic value of the KRAS mutation in Chinese colorectal cancer patients. Int J Biol Markers. 2021;36(2):33–39. doi:10.1177/17246008211017152
   PubMed Web of Science ®Google Scholar
• Chang XN, Shang FM, Jiang HY, et al. Clinicopathological Features and Prognostic Value of KRAS/NRAS/BRAF Mutations in Colorectal Cancer Patients of Central China. Curr Med Sci. 2021;41(1):118–126. doi:10.1007/s11596-021-2326-1
   PubMed Web of Science ®Google Scholar
• Song Y, Wang L, Ran W, et al. Effect of tumor location on clinicopathological and molecular markers in colorectal cancer in eastern china patients: an analysis of 2356 cases. Front Genet. 2020;11:96. doi:10.3389/fgene.2020.00096
   PubMed Web of Science ®Google Scholar
• Guo F, Gong H, Zhao H, et al. Mutation status and prognostic values of KRAS, NRAS, BRAF and PIK3CA in 353 Chinese colorectal cancer patients. Sci Rep. 2018;8(1):6076. doi:10.1038/s41598-018-24306-1
   PubMedGoogle Scholar
• Ounissi D, Weslati M. Clinicopathological characteristics and mutational profile of KRAS and NRAS in Tunisian patients with sporadic colorectal cancer. Turk J Med Sci. 2021;51(1):148–158. doi:10.3906/sag-2003-42
   PubMed Web of Science ®Google Scholar
• Sanchez-Ibarra HE, Jiang X, Gallegos-Gonzalez EY, et al. KRAS, NRAS, and BRAF mutation prevalence, clinicopathological association, and their application in a predictive model in Mexican patients with metastatic colorectal cancer: a retrospective cohort study. PLoS One. 2020;15(7):e0235490. doi:10.1371/journal.pone.0235490
   PubMed Web of Science ®Google Scholar
• Yang Q, Huo S, Sui Y, et al. Mutation Status and Immunohistochemical Correlation of KRAS, NRAS, and BRAF in 260 Chinese Colorectal and Gastric Cancers. Front Oncol. 2018;8:487. doi:10.3389/fonc.2018.00487
   PubMed Web of Science ®Google Scholar
• Negru S, Papadopoulou E, Apessos A, et al. KRAS, NRAS and BRAF mutations in Greek and Romanian patients with colorectal cancer: a cohort study. BMJ Open. 2014;4(5):e004652. doi:10.1136/bmjopen-2013-004652
   PubMed Web of Science ®Google Scholar
• Wang Y, Liu H, Hou Y, et al. Performance validation of an amplicon-based targeted next-generation sequencing assay and mutation profiling of 648 Chinese colorectal cancer patients. Virchows Arch. 2018;472(6):959–968. doi:10.1007/s00428-018-2359-4
   PubMed Web of Science ®Google Scholar
• Zhang X, Wu J, Wang L, Zhao H, Li H. HER2 and BRAF mutation in colorectal cancer patients: a retrospective study in Eastern China. Peer J. 2020;8:e8602. doi:10.7717/peerj.8602
   PubMed Web of Science ®Google Scholar
• Jia X, Li B, Wang H, Yan Z. Clinical features, molecular alterations and prognosis of colorectal adenocarcinoma with mucinous component in Chinese patients. Appl Immunohistochem Mol Morphol. 2021;29(10):765–772. doi:10.1097/PAI.0000000000000950
   PubMedGoogle Scholar
• Al-Shamsi HO, Jones J, Fahmawi Y, et al. Molecular spectrum of KRAS, NRAS, BRAF, PIK3CA, TP53, and APC somatic gene mutations in Arab patients with colorectal cancer: determination of frequency and distribution pattern. J Gastrointest Oncol. 2016;7(6):882–902. doi:10.21037/jgo.2016.11.02
   PubMed Web of Science ®Google Scholar
• Reggiani Bonetti L, Barresi V. Clinical Impact and Prognostic Role of KRAS/BRAF/PIK3CA Mutations in Stage I Colorectal Cancer. Dis Markers. 2018;2018:2959801. doi:10.1155/2018/2959801
   PubMed Web of Science ®Google Scholar
• Fu X, Lin H, Fan X, et al. The Spectrum, Tendency and Predictive Value of PIK3CA Mutation in Chinese Colorectal Cancer Patients. Front Oncol. 2021;11:595675. doi:10.3389/fonc.2021.595675
   PubMed Web of Science ®Google Scholar
• Chang YS, Lee CC, Ke TW, et al. Molecular characterization of colorectal cancer using whole-exome sequencing in a Taiwanese population. Cancer Med. 2019;8(8):3738–3747. doi:10.1002/cam4.2282
   PubMed Web of Science ®Google Scholar
• Liu J, Zeng W, Huang C, Wang J, Xu L, Ma D. Upregulation of c-mesenchymal epithelial transition expression and RAS mutations are associated with late lung metastasis and poor prognosis in colorectal carcinoma. Exp Ther Med. 2018;15(5):4229–4242. doi:10.3892/etm.2018.5966
   PubMed Web of Science ®Google Scholar
• Li Z, Chen Y, Wang D, Wang G, He L, Suo J. Detection of KRAS mutations and their associations with clinicopathological features and survival in Chinese colorectal cancer patients. J Int Med Res. 2012;40(4):1589–1598. doi:10.1177/147323001204000439
   PubMed Web of Science ®Google Scholar
• Jin J, Shi Y, Zhang S, Yang S. PIK3CA mutation and clinicopathological features of colorectal cancer: a systematic review and Meta-Analysis. Acta Oncol. 2020;59(1):66–74. doi:10.1080/0284186X.2019.1664764
   PubMed Web of Science ®Google Scholar
• Adeleke S, Haslam A, Choy A, Diaz-Cano S, Galante JR. Microsatellite instability testing in colorectal patients with Lynch syndrome: lessons learned from a case report and how to avoid such pitfalls. Per Med. 2022;19(4):277–286. doi:10.2217/pme-2021-0128
   PubMedGoogle Scholar
• Liu H, Liang Z, Zhou C, et al. Mutant KRAS triggers functional reprogramming of tumor-associated macrophages in colorectal cancer. Signal Transduct Target Ther. 2021;6(1):144. doi:10.1038/s41392-021-00534-2
   PubMed Web of Science ®Google Scholar
• Ye YP, Wu P, Gu CC, et al. miR-450b-5p induced by oncogenic KRAS is required for colorectal cancer progression. Oncotarget. 2016;7(38):61312–61324. doi:10.18632/oncotarget.11016
   PubMedGoogle Scholar
• Zhi J, Jia XJ, Yan J, et al. BRAF(V600E) mutant colorectal cancer cells mediate local immunosuppressive microenvironment through exosomal long noncoding RNAs. World J Gastrointest Oncol. 2021;13(12):2129–2148. doi:10.4251/wjgo.v13.i12.2129
   PubMed Web of Science ®Google Scholar
• Herr R, Köhler M, Andrlová H, et al. B-Raf inhibitors induce epithelial differentiation in BRAF-mutant colorectal cancer cells. Cancer Res. 2015;75(1):216–229. doi:10.1158/0008-5472.CAN-13-3686
   PubMed Web of Science ®Google Scholar
• Boraschi P, Donati F, Cervelli R, et al. Colorectal liver metastases: ADC as an imaging biomarker of tumor behavior and therapeutic response. Eur J Radiol. 2021;137:109609. doi:10.1016/j.ejrad.2021.109609
   PubMed Web of Science ®Google Scholar
• Lah TT, Novak M, Breznik B. Brain malignancies: glioblastoma and brain metastases. Semin Cancer Biol. 2020;60:262–273. doi:10.1016/j.semcancer.2019.10.010
   PubMed Web of Science ®Google Scholar
• Borgomaneri S, Battaglia S, Sciamanna G, Tortora F, Laricchiuta D. Memories are not written in stone: re-writing fear memories by means of non-invasive brain stimulation and optogenetic manipulations. Neurosci Biobehav Rev. 2021;127:334–352. doi:10.1016/j.neubiorev.2021.04.036
   PubMed Web of Science ®Google Scholar
• Borgomaneri S, Battaglia S, Avenanti A, Pellegrino GD. Don’t Hurt Me No More: state-dependent Transcranial Magnetic Stimulation for the treatment of specific phobia. J Affect Disord. 2021;286:78–79. doi:10.1016/j.jad.2021.02.076
   PubMed Web of Science ®Google Scholar
• Tanaka M, Vécsei L. Editorial of Special Issue “Crosstalk between Depression, Anxiety, and Dementia: comorbidity in Behavioral Neurology and Neuropsychiatry”. Biomedicines. 2021;9(5):517. doi:10.3390/biomedicines9050517
   PubMed Web of Science ®Google Scholar
• Spekker E, Tanaka M, Szabó Á, Vécsei L. Neurogenic Inflammation: the Participant in Migraine and Recent Advancements in Translational Research. Biomedicines. 2021;10(1):76. doi:10.3390/biomedicines10010076
   PubMed Web of Science ®Google Scholar